VIVES is a multi-sector fund that invests in projects with a positive societal impact
ExeVir is a clinical-stage company developing antiviral therapies using its VHH technology platform to provide broad protection against viral infections, including coronaviruses. The platform builds...
Botalys has developed a vertical farming technology that enables the production of rare plants and high-value ingredients for the food supplement, cosmetics, and pharmaceutical industries. This...
Spinovit, a UCLouvain spin-off, is developing a method for the quantitative analysis of an oxygen-sensitive blood biomarker to measure endothelial dysfunction and prevent cardiovascular risks.
Cardio...
David Frenay, CEO Emolytics:
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
Pierre-Antoine Mariage, co-CEO Botalys:
"VIVES trusted us at an early stage. In addition to their financial investment, they offer us a regular and wise coaching from their experts while respecting...
Denis Périquet, CEO Tessares:
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is